Skip to content

JAPAN

Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab

Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab

Anthos Therapeutics Manje od 26% kineskih pacijenata sa atrijalnom fibrilacijom prepisuje antikoagulans, dok se u Japanu gotovo jedna trećina pacijenata ne liječi Otprilike 63% pacijenata… Read More »Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab